ArticleKidney diseases (Basel, Switzerland)
Light chain Cast Nephropathy: The Relationship between Tamm-Horsfall Protein Immunoreactivity and Clinical Pathological Features and Prognosis.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Light chain cast nephropathy (LCCN) results from the coprecipitation of monoclonal light chains with Tamm-Horsfall protein (THP) within the distal nephron, which forms obstructive casts. Although previous studies have suggested that crystalline LCCN variants may develop independently of THP, the role of THP in classic LCCN remains unclear. We investigated THP involvement in diverse LCCN variants and compared the clinicopathological profiles and outcomes of THP-positive and THP-negative cohorts. Methods: We retrospectively analyzed 32 patients with newly diagnosed multiple myeloma and biopsy-proven LCCN. Cases were classified as THP-positive ( Results: Immunoreactive-negative THP LCCN, accounting for 40.6% (13/32) of the cohort, presented with significantly lower hemoglobin, higher serum creatinine, more frequent acute kidney injury (AKI), and greater dialysis dependence than their THP-immunoreactive-positive counterparts. Immunoreactive-negative THP patients exhibited exacerbated tubular atrophy, interstitial inflammation, and acute tubular injury. Mass spectrometry further confirmed that THP was undetectable in a portion of immunoreactive-negative THP casts. No significant between-group difference was observed in survival. Conclusion: Immunoreactive-negative THP LCCN correlates with severe anemia, AKI requiring dialysis, and marked tubular damage. Therefore, immunohistochemical staining for THP should be carefully evaluated in patients with LCCN. Further exploration of the mechanisms underlying LCCN pathogenesis is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.